Please assess the completion status of the following clinical trial:

Trial Title: Add-on Sodium Nitroprusside to Treatment as Usual in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of schizophrenia~* Patients in an acute psychotic episode requiring full hospitalization~Exclusion Criteria:~* Significant medical conditions (heart, kidney, liver, thyroid or neurological diseases, hypovitaminosis B12, hyponatremia)~* Pregnancy~* Breastfeeding~* Previous hypersensitivity to sodium nitroprusside~* DSM-IV diagnosis of drug abuse or dependence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Sodium nitroprusside (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): Glucose solution 5%

Based on this trial design, predict the completion outcome and termination type (if applicable).